Home - Products - Others - Other Targets - MCA-SEVNLDAEFR-K(Dnp)-RR, amide

MCA-SEVNLDAEFR-K(Dnp)-RR, amide

CAS No. 438625-61-7

MCA-SEVNLDAEFR-K(Dnp)-RR, amide( —— )

Catalog No. M30204 CAS No. 438625-61-7

MCA-SEVNLDAEFR-K(Dnp)-RR, amide is a FRET-based substrate.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    MCA-SEVNLDAEFR-K(Dnp)-RR, amide
  • Note
    Research use only, not for human use.
  • Brief Description
    MCA-SEVNLDAEFR-K(Dnp)-RR, amide is a FRET-based substrate.
  • Description
    MCA-SEVNLDAEFR-K(Dnp)-RR, amide is a FRET-based substrate.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    438625-61-7
  • Formula Weight
    2001.08
  • Molecular Formula
    C86H125N27O29
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:MCA-{Ser}{Glu}{Val}{Asn}{Leu}{Asp}{Ala}{Glu}{Phe}{Arg}{Lys(Dnp)}{Arg}{Arg}-NH2

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Orexin A (human, rat...

    Orexin A human, rat, mouse, a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A human, rat, mouse has been used to study its effect on the functioning of porcine pancreatic islets. It has also been used as an orexin receptor 1 (OX1R) antagonist to study the effect of orexin systems in the effect of etonogestrel on respiratory response to prolonged metabolic acidosis.

  • SYA 006

    SYA 006 can be used to make adhesives for ophthalmic surgery.

  • DCZ0415

    DCZ0415 induces antimyeloma activity in vitro, in vivo and in primary cells of drug-resistant myeloma patients. DCZ0415 is a potent TRIP13 inhibitor that can impair the repair of non-homologous end junctions and inhibit NF-κB activity.DCZ0415 (10, 20 μM; 72 hours) showed a marked reduction in colony formation, indicating that it inhibited cell proliferation.